Clinical Trials
Open
Phase
II-III
Accrual
0%
SWOG Clinical Trial Number
S2012
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Status Notes
Activation: Effective December 02, 2021 at 2:00 p.m. Eastern.
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
12-02-2021
ClinicalTrials.gov Registry Number
NCT05058651
Open
Phase
III
Accrual
0%
SWOG Clinical Trial Number
S2011
Randomized Phase II Trial Of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery For Cisplatin-Ineligible Muscle-Ineligible Urothelial Carcinoma: SWOG GAP TRIAL
Status Notes
The study referenced above is open for participant accrual effective October 6th, 2021, at 12:00 p.m. Eastern Time.
Research Committee(s)
Genitourinary Cancer
Activated
10-06-2021
ClinicalTrials.gov Registry Number
04871529
Open
Accrual
0%
SWOG Clinical Trial Number
S1934
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
Status Notes
S1934 will be temporarily closed to accrual, effective immediately on November 5, 2021.
Research Committee(s)
Lung Cancer
Activated
09-09-2021
ClinicalTrials.gov Registry Number
04989283
Open
Phase
II
Accrual
2%
SWOG Clinical Trial Number
S2013
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Status Notes
S2013 will open to accrual on August 16, 2021, effective 12:00 pm PST.
Research Committee(s)
Symptom Control and Quality of Life
Activated
08-16-2021
Open
Accrual
1%
SWOG Clinical Trial Number
S1912CD
A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Status Notes
All protocol documents will be accessible from the S1912CD protocol abstract page on www.ctsu.org (login required).
Research Committee(s)
Cancer Care Delivery
Activated
07-26-2021
ClinicalTrials.gov Registry Number
NCT 04960787
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2005
A Phase II Randomized Study of Ibrutinib and Rituximab with or without Venetoclax in Previously Untreated Waldenstrom's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)
Status Notes
Re-Activation – Effective (9/20/2021)
Research Committee(s)
Myeloma
Activated
06-24-2021
ClinicalTrials.gov Registry Number
04840602